Repligen Stock Today
| RGEN Stock | USD 167.86 3.42 2.00% |
Performance0 of 100
| Odds Of DistressLess than 9
|
Repligen is selling at 167.86 as of the 24th of April 2024; that is -2 percent decrease since the beginning of the trading day. The stock's open price was 171.28. Repligen has less than a 9 % chance of experiencing financial distress in the next few years, but has generated negative returns over the last 90 days. Equity ratings for Repligen are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 27th of October 2023 and ending today, the 24th of April 2024. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 26th of March 1990 | Category Healthcare | Classification Health Care |
Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. Repligen Corporation was incorporated in 1981 and is headquartered in Waltham, Massachusetts. The company has 55.84 M outstanding shares of which 4.77 M shares are at this time shorted by private and institutional investors with about 12.26 trading days to cover. More on Repligen
Moving together with Repligen Stock
| 0.69 | DRMA | Dermata Therapeutics Financial Report 9th of May 2024 | PairCorr |
Moving against Repligen Stock
| 0.77 | ACB | Aurora Cannabis Trending | PairCorr |
| 0.74 | YS | YS Biopharma | PairCorr |
| 0.73 | ELYM | Eliem Therapeutics | PairCorr |
| 0.72 | DSGN | Design Therapeutics Downward Rally | PairCorr |
| 0.71 | CGC | Canopy Growth Corp Trending | PairCorr |
| 0.65 | FUSN | Fusion PharmaceuticalsInc Financial Report 9th of May 2024 | PairCorr |
| 0.56 | XFOR | X4 Pharmaceuticals Financial Report 2nd of May 2024 | PairCorr |
Repligen Stock Highlights
Most reasonable investors view market volatility as an opportunity to invest at a favorable price or to sell short against a bearish trend. Repligen's investment highlights are automatically generated signals that are significant enough to either complement your investing judgment regarding Repligen or challenge it. These highlights can help you better understand the position you are entering and avoid costly mistakes.
| President CEO, Director | Anthony Hunt | ||||
| Thematic Ideas | (View all Themes) | ||||
| Business Concentration | Life Sciences Tools & Services, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Composite, ARCA Biotechnology, SP Midcap 400, NASDAQ Composite Total, NASDAQ Health Care, Office Supplies, Health Management, Health Care, Life Sciences Tools & Services, Medical Instruments & Supplies, Healthcare (View all Sectors) | ||||
| Average Analyst Recommendation Analysts covering Repligen report their recommendations after researching Repligen's financial statements, talking to executives and customers, or listening in on Repligen's conference calls. The current trade recommendation is based on an ongoing consensus estimate among financial analysts covering Repligen. The Repligen consensus assessment is calculated by taking the average forecast from all of the analysts covering Repligen. | |||||
Repligen's financial strength is of vital concern to both outside investors and internal stakeholders. Efficiency and cost control are keys to Repligen's success, along with its ability to generate sufficient cash flow to pay bills, repay debt, and make a consistent year-to-year profit. | |||||
Financial leverage usually refers to the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Repligen's financial leverage. It provides some insight into what part of Repligen's total assets is financed by creditors.
| |||||
Repligen (RGEN) is traded on NASDAQ Exchange in USA. It is located in Building 1, Waltham, MA, United States, 02453 and employs 1,783 people. Repligen is listed under Life Sciences Tools & Services category by Fama And French industry classification. The company currently falls under 'Mid-Cap' category with a current market capitalization of 9.56 B. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Repligen's market, we take the total number of its shares issued and multiply it by Repligen's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities. Repligen conducts business under Life Sciences Tools & Services sector and is part of Health Care industry. The entity has 55.84 M outstanding shares of which 4.77 M shares are at this time shorted by private and institutional investors with about 12.26 trading days to cover.
Repligen currently holds about 596.51 M in cash with 113.92 M of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 10.75.
Check Repligen Probability Of Bankruptcy
Ownership AllocationRepligen has a total of 55.84 Million outstanding shares. The majority of Repligen outstanding shares are owned by third-party entities. These institutional holders are usually referred to as non-private investors looking to secure positions in Repligen to benefit from reduced commissions. Consequently, institutional investors are subject to a different set of regulations than regular investors in Repligen. Please pay attention to any change in the institutional holdings of Repligen as this could imply that something significant has changed or is about to change at the company. Note that regardless of who owns the company, if the true value of the entity is less than the market is willing to pay for it, you may not be able to generate positive returns over time.
Check Repligen Ownership Details
Repligen Stock Price Odds Analysis
Contingent on a normal probability distribution, the odds of Repligen jumping above the current price in 90 days from now is under 95%. The Repligen probability density function shows the probability of Repligen stock to fall within a particular range of prices over 90 days. Given the investment horizon of 90 days the stock has a beta coefficient of 2.2358 indicating as the benchmark fluctuates upward, the company is expected to outperform it on average. However, if the benchmark returns are projected to be negative, Repligen will likely underperform. Additionally, repligen has a negative alpha, implying that the risk taken by holding this instrument is not justified. The company is significantly underperforming the NYSE Composite.
Based on a normal probability distribution, the odds of Repligen to move above the current price in 90 days from now is under 95 (This Repligen probability density function shows the probability of Repligen Stock to fall within a particular range of prices over 90 days) .
Repligen Stock Institutional Holders
Institutional Holdings refers to the ownership stake in Repligen that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Repligen's outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Repligen's value.| Instituion | Recorded On | Shares | |
| Wellington Management Company Llp | 2023-12-31 | 1.1 M | |
| Impax Asset Management Group Plc | 2023-09-30 | 972.7 K | |
| Champlain Investment Partners, Llc | 2023-12-31 | 926.4 K | |
| William Blair Investment Management, Llc | 2023-12-31 | 905.8 K | |
| Geode Capital Management, Llc | 2023-09-30 | 852.2 K | |
| Amvescap Plc. | 2023-12-31 | 833.1 K | |
| Alliancebernstein L.p. | 2023-09-30 | 785.1 K | |
| Harding Loevner L.p. | 2023-12-31 | 716.3 K | |
| Conestoga Capital Advisors, Llc | 2023-12-31 | 709.7 K | |
| Blackrock Inc | 2023-12-31 | 7.9 M | |
| Vanguard Group Inc | 2023-09-30 | 5 M |
Repligen Historical Income Statement
Repligen Income Statement is one of the three primary financial statements used for reporting Repligen's overall financial performance over a current year or for a given accounting period. An Income Statement sometimes referred to as the statement of Repligen revenue and expense. Repligen Income Statement primarily focuses on the company's revenues and expenses during a particular period.
At this time, Repligen's EBITDA is very stable compared to the past year. As of the 24th of April 2024, Income Before Tax is likely to grow to about 67.3 M, while Depreciation And Amortization is likely to drop about 43.7 M. View More FundamentalsRepligen Stock Against Markets
Picking the right benchmark for Repligen stock is fundamental to making educated investment choices. Many naive investors compare their positions with the S&P 500 or with the Nasdaq. But these benchmarks are not all-inclusive and generally should be used only for large-capitalization equities or stock offerings from large companies. When the price of a selected benchmark declines in a down market, there may be an uptick in Repligen stock price where buyers come in believing the asset is cheap. The opposite is true when the market is bullish; so, accurately picking the benchmark for Repligen is critical whether you are bullish or bearish towards Repligen at a given time. Please also check how Repligen's historical prices are related to one of the top price index indicators.
Be your own money manager
Our tools can tell you how much better you can do entering a position in Repligen without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.Did you try this?
Run Competition Analyzer Now
Competition AnalyzerAnalyze and compare many basic indicators for a group of related or unrelated entities |
| All Next | Launch Module |
Repligen Corporate Directors
Repligen corporate directors refer to members of a Repligen board of directors. The board of directors generally takes responsibility for the Repligen's affairs and long-term direction of the entity. A corporate director does not make decisions for the corporation on his own. As a member of the board of directors, she or he must function as a part of a group that makes decisions on behalf of the business only by the board of directors' meetings. To pass a resolution, a majority of Repligen's board members must vote for the resolution. The Repligen board of directors' duties also include the election, removal, and supervision of officers, including the adoption, amendment, and repeal of bylaws.| Thomas Ryan | Independent Director | Profile | |
| Glenn Muir | Director | Profile | |
| Alfred Goldberg | Independent Director | Profile | |
| Glenn Cooper | Independent Director | Profile |
How to buy Repligen Stock?
Before investing in Repligen, you must ensure you fully understand your financial goals and how diversified (or not) your overall investments are now. Then, after you clearly understand your investment objectives, consider investing in Repligen. To buy Repligen stock, you can follow these steps:- Choose a brokerage firm: You need to select a brokerage firm to buy shares of Repligen. Some popular options include Charles Schwab, Fidelity, TD Ameritrade, and Robinhood.
- Open an account: Once you have chosen a brokerage firm, you will need to open an account. You will be required to provide personal information, such as your name, address, and Social Security number.
- Fund your account: You will need to deposit funds into your brokerage account to purchase Repligen stock. You can do this by transferring funds from your bank account or other investment accounts.
- Place your order: Once you have located Repligen stock in your brokerage account, you can place your order to buy it. You will need to specify the number of shares you want to buy and the price you are willing to pay.
- Monitor your investment: After you have purchased Repligen stock, you should monitor your investment to track its performance and make informed decisions about buying, selling, or holding the stock
It's important to note that investing in stocks, such as Repligen, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember various factors, including economic indicators, change in net worth, political events, company-specific news, and investor sentiment, can influence the stock market. These factors can cause fluctuations in stock prices and lead to market volatility affecting your buy or sell decision. However, volatility can also present opportunities for investors to make gains by buying stocks when prices are low and selling when they are high. It's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. For more information on how to buy Repligen Stock please use our How to Invest in Repligen guide.
Already Invested in Repligen?
The danger of trading Repligen is mainly related to its market volatility and Company specific events. As an investor, you must understand the concept of risk-adjusted return before you start trading. The most common way to measure the risk of Repligen is by using the Sharpe ratio. The ratio expresses how much excess return you acquire for the extra volatility you endure for holding a more risker asset than Repligen. The Sharpe ratio is calculated by using standard deviation and excess return to determine reward per unit of risk. To understand how volatile Repligen is, you must compare it to a benchmark. Traditionally, the risk-free rate of return is the rate of return on the shortest-dated U.S. Treasury, such as a 3-year bond.
When determining whether Repligen offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Repligen's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Repligen Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Repligen Stock: Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Repligen. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in income. To learn how to invest in Repligen Stock, please use our How to Invest in Repligen guide.Note that the Repligen information on this page should be used as a complementary analysis to other Repligen's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Global Correlations module to find global opportunities by holding instruments from different markets.
Complementary Tools for Repligen Stock analysis
When running Repligen's price analysis, check to measure Repligen's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Repligen is operating at the current time. Most of Repligen's value examination focuses on studying past and present price action to predict the probability of Repligen's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Repligen's price. Additionally, you may evaluate how the addition of Repligen to your portfolios can decrease your overall portfolio volatility.
| Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
| Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites | |
| FinTech Suite Use AI to screen and filter profitable investment opportunities | |
| USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA | |
| Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
| Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
| Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
| Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios | |
| Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
| Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. | |
| Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
| ETFs Find actively traded Exchange Traded Funds (ETF) from around the world |
Is Repligen's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Repligen. If investors know Repligen will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Repligen listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.55) | Earnings Share 0.74 | Revenue Per Share 11.464 | Quarterly Revenue Growth (0.17) | Return On Assets 0.0131 |
The market value of Repligen is measured differently than its book value, which is the value of Repligen that is recorded on the company's balance sheet. Investors also form their own opinion of Repligen's value that differs from its market value or its book value, called intrinsic value, which is Repligen's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Repligen's market value can be influenced by many factors that don't directly affect Repligen's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Repligen's value and its price as these two are different measures arrived at by different means. Investors typically determine if Repligen is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Repligen's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.